2025
A Transformative Year for GI Health,
Thanks to You.
A Message from Our Founders
"
2025 has been a defining year for Nimble Science. Together with our partners and clients, we’ve advanced the boundaries of GI health research, transforming curiosity into clinical and commercial impact.
Thank you for your continued trust and collaboration.
​​
​
Sabina & Joseph, Co-Founders, Nimble Science
"
2025 Highlights
Regulatory Progress
Health Canada Class II Medical Device License achieved for SIMBA™ Capsule in Canada. In all other global jurisdictions, it is used as an investigational device in authorized studies.
Strengthening of the Advisory Board and Leadership
-
Prof. Eran Segal, a globally recognized computational biologist at the Weizmann Institute of Science, has joined the Nimble Science team as a Scientific Advisor. With deep expertise in personalized medicine and nutrition, and in the complex interplay between genetics, the microbiome, and human health, Prof. Segal will help strategically guide Nimble as it leverages its rapidly growing precision small-intestinal database.
-
Corundum Systems Biology joins Nimble Science as a new investor, supporting the company’s mission to advance precision insights into small intestinal health and data.
Scientific Discovery
-
Successfully deployed over 1200 devices across 8 countries in North-America and EU, generating multi-omic data from the small intestine of healthy and diseased cohorts.
-
The MRM Partnered study on Parkinson’s Disease concludes with new insights on microbial composition
differences in the small intestine that challenge current targets based on solely sampling fecal samples.
-
The Fonterra study demonstrates distinct, peptide signatures in the small intestine, capturing dynamic digestion kinetics and the emergence of peptides across early and late post-prandial windows.
-
Early FMT results from Nimble's Discovery study reveal that the small intestinal microbiota is far more sensitive to antibiotic treatment than the fecal microbiota, highlighting the need to consider regional differences when assessing antibiotic and other interventional impact on the gut microbiome.
-
Pilot data from antibiotic treated participants in the Discovery study reveal distinct pre- and post-treatment microbial shifts in the small intestine that remain undetected in matched fecal samples, underscoring SIMBA™ Capsule’s ability to capture clinically meaningful luminal signatures.
-
The Wageningen University & Research study (TAPIR) demonstrated that SIMBA™ Capsule can safely and reliably replace trans-nasal catheter aspirates, enabling multi-omic assessment of dietary fat responses with far higher sampling success.
Partnerships Expanded
Cmbio finalizes MSA with Nimble Science as reseller of the SIMBA™ Capsule in Europe and North America
Clinical Studies paving new roads
Beyond advancing understanding of GI disorders through direct small-intestinal sampling, SIMBA™ Capsule is also informing research across systemic conditions—including Diabetes, Liver disease, Pre-eclampsia, Multiple Sclerosis and Parkinson’s—highlighting the broader role of the gut microbiome in human health.
Platform Launch
Introduced the GI Health Data Platform to deliver actionable data insights, with Nimble’s growing cohort of healthy participant data made available to customers for benchmarking and scientific discovery.
New Use Cases
Validated new use cases in timed collection of small intestinal samples to study pharmacokinetics, bioavailability, and food digestion kinetics. This work demonstrates how SIMBA™ Capsule enables time-resolved sampling of the small intestine to directly measure digestion and absorption processes, generating insights that cannot be captured through fecal or systemic sampling alone.
Product Innovation
Introduced new eco-friendly basins for capsule retrieval. A new colon targeting capsule used in first clinical investigations.
Conferences & Community
This year Nimble Science was featured at leading global conferences, including Probiota America (Vancouver), BioJapan (Yokohama), MANA (Banff), and Global Engage’s Microbiome, R&D and Business Collaborations (USA), among others. In early 2026, we have been invited to present our findings at the Pharmabiotic Research Institute Conference in Belgium and Digestive Disease Week (DDW) in Chicago. The Nimble team will also be attending several additional events in Q1, including Microbiome, Metabolism & Metabolites (Banff), DxPx (Munich), C100 (San Francisco), the Microbiome Times Partnering Forum (Copenhagen), and Probiota Global (Dublin). We look forward to seeing you in 2026!
Looking Ahead to 2026
-
Launching new clinical studies in oncology and pharmacology to broaden our scientific impact.
-
Expanding our data partnerships across North America, Asia, and Europe to support global-scale discovery.
-
Continuing to evolve the GI Health Data Platform with strengthened analytics and cohort intelligence.
Davide Martino-LENSER Study
Active enrolment for Parkinson’s Disease patients to explore the relationship between small intestinal microbiome and Levodopa.
Participants: 38
Status: Active Enrollment
Lallemand Health Solutions
Actively enrolling SIBO patients for a safety and efficacy trial evaluating probiotic intervention.
Participants: 57
Status: Active Enrollment
Fonterra
Completed enrollment of healthy participants in a milk protein concentrate study to examine absorption and digestion kinetics.
Participants: 22
Status: Completed Enrollment
Analysis Active
Wageningen University and Research
The TAPIR (HealThy fAt, haPpy mIcRobiome )study concluded with interesting data showing microbiota-derived lipids in small intestine was captured better using SIMBA™ Capsule than naso-intestinal catheters.
Participants: 16
Status: Completed
Location: The Netherlands
FEATURED STUDY
Nimble Science’s DISCOVERY STUDY
Actively enrolling healthy participants and GI-disordered cohorts (e.g., IBS) to deepen our understanding of the small intestinal microbiome and further advance the GI Health Data Platform.
Participants: 300
Status: Active Enrollment
Taylored Bioherapeutics
Active enrollment of OCD participants for a safety and efficacy trial evaluating fecal microbiota transplantation (FMT).
Participants: 17
Status: Active Enrollment
Johannes Keplar University
Actively enrolling healthy volunteers and SIBO patients in the SIBOme study to explore differences in microbial composition and host interactions between the two groups.
Participants: 30 in each cohort
Status: Active Enrollment
Location: Austria
Actively recruiting for a nutraceutical company evaluating a supplement for diabetic adults.
To learn more, check out our current studies.
Now Recruiting
Our Clients Say
"Testimonials provide a sense of what it's like to work with you, or what it's like to use your products and services."
xxxxx
Data Snapshot
Animal vs Human
DSP Projects
Human Studies by Clinical Indication
